Journal of the American Heart Association · 2026
Continuous Versus Intermittent Loop Diuretics Step-by-Step Protocol in Acute Heart Failure (DIUR-AHF): A Propensity-Matched Analysis.
СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ruocco Gaetano, Salzano Andrea, Franceschi Sara, Lorusso Roberto, Pirrotta Filippo, Stefanini Andrea, Pagliaro Antonio, Severino Paolo, D'Amato Andrea, Vizza Carmine D, Crisci Giulia, Guazzi Marco, Frea Simone, Pastorini Guido, Feola Mauro, Fedele Francesco, Palazzuoli Alberto
Аннотация
BACKGROUND: Loop diuretics are used to solve congestion in acute heart failure. However, a clear indication about the best infusion modality, dose, and duration of the treatment has not yet been established. In this analysis of the DIUR-AHF (Different Loop Diuretic Dosing and Administration in Acute Heart Failure) study, we aimed to investigate the effects of different diuretic administration modalities (ie, intermittent versus continuous furosemide infusion) and dose (high dose [HD] versus low dose) on congestion, renal function, and outcome.
METHODS: Patients received intermittent or continuous intravenous loop diuretics infusion combined as a 1:1 ratio for a period of 72 to 120 hours. HD was defined as a high loop diuretic dose >120 mg/d. Clinical outcome was evaluated in terms of death or heart failure rehospitalization over a 6-month follow-up period.
RESULTS: A total of 370 patients with AHF were included in this analysis, 189 treated with continuous intravenous loop diuretics infusion and 181 with intermittent intravenous loop diuretics infusion. At baseline, the continuous intravenous loop diuretic infusion group showed increased median values of blood urea (P=0.010) and creatinine (P=0.017). Dividing our sample according to loop diuretic dosage, the HD group revealed similar congestion and weight loss compared with the low-dose group; however, the HD group showed a reduced diuretic efficiency (-0.13 [-0.22 to -0.07] versus -0.32 [-0.59 to -0.20] kg/d; P<0.001) and an increased rate of adverse event occurrence (55% versus 20%; P<0.001). Multivariable analysis showed the association between HD treatment and poor postdischarge outcome (hazard ratio, 1.95 [95% CI, 1.23-3.10]; P=0.005).
CONCLUSIONS: An HD of loop diuretics infusion revealed an increased risk for adverse events together with reduced diuretic response. Our results extend previous findings revealing the association between HD diuretics and prognosis in patients with chronic HF. Additional studies may confer loop diuretic response in relation to the other decongestive treatments.
METHODS: Patients received intermittent or continuous intravenous loop diuretics infusion combined as a 1:1 ratio for a period of 72 to 120 hours. HD was defined as a high loop diuretic dose >120 mg/d. Clinical outcome was evaluated in terms of death or heart failure rehospitalization over a 6-month follow-up period.
RESULTS: A total of 370 patients with AHF were included in this analysis, 189 treated with continuous intravenous loop diuretics infusion and 181 with intermittent intravenous loop diuretics infusion. At baseline, the continuous intravenous loop diuretic infusion group showed increased median values of blood urea (P=0.010) and creatinine (P=0.017). Dividing our sample according to loop diuretic dosage, the HD group revealed similar congestion and weight loss compared with the low-dose group; however, the HD group showed a reduced diuretic efficiency (-0.13 [-0.22 to -0.07] versus -0.32 [-0.59 to -0.20] kg/d; P<0.001) and an increased rate of adverse event occurrence (55% versus 20%; P<0.001). Multivariable analysis showed the association between HD treatment and poor postdischarge outcome (hazard ratio, 1.95 [95% CI, 1.23-3.10]; P=0.005).
CONCLUSIONS: An HD of loop diuretics infusion revealed an increased risk for adverse events together with reduced diuretic response. Our results extend previous findings revealing the association between HD diuretics and prognosis in patients with chronic HF. Additional studies may confer loop diuretic response in relation to the other decongestive treatments.